Best Gallbladder Cancer Hospital in Hyderabad — 11 Centres, NCCN Protocols, NABH-Accredited Partners

Gallbladder cancer surgery sits in the same technical territory as liver and pancreatic surgery — it needs a surgeon specifically trained in hepatobiliary (HPB) surgery, capable of working in close proximity to major blood vessels, the bile ducts, and the liver. Around the surgeon, the team needs a medical oncologist experienced with biliary tract cancer chemotherapy regimens (particularly gemcitabine + cisplatin and the newer durvalumab immunotherapy combinations), a radiation oncologist for selected high-risk cases, an interventional gastroenterologist who can perform ERCP for biliary stenting when jaundice is present, an interventional radiologist for percutaneous biliary drainage if needed, a pathologist with hepatobiliary cancer experience, and hepatologist support when liver function is affected. Ask for named team credentials in writing.

Walk away if the surgery is to be performed by a general surgeon without specific HPB training, particularly for cases beyond T1a.

A gallbladder cancer tumour board reviews imaging (CT, MRI, MRCP for bile duct anatomy), biopsy or post-cholecystectomy histopathology, and biomarker test results together. The board assigns a TNM stage, debates the surgical approach (simple cholecystectomy for T1a vs extended radical for T1b and beyond), plans completion radical cholecystectomy for incidental cases, and decides on adjuvant chemotherapy. For locally advanced cases, neoadjuvant chemotherapy followed by surgery may be discussed. For unresectable or metastatic disease, biomarker-driven systemic therapy choices are made.

Walk away if surgery is recommended in the first consultation without a documented tumour-board discussion that considers the appropriate extent of resection.

Gallbladder cancer surgery has a strong volume-outcome relationship. Extended radical cholecystectomy — combining gallbladder removal with resection of liver segments IVb and V (the gallbladder bed) and removal of regional lymph nodes along the hepatoduodenal ligament — is the curative-intent operation for cancers beyond T1a. The most important measurable outcome is the R0 resection rate (resection with clear microscopic margins) — incomplete resection (R1 or R2) significantly compromises survival. Ask: 'How many extended radical cholecystectomies did your team perform last year? How many completion radical operations for incidental cancers? What is your R0 resection rate?' Specific numbers indicate transparency.

Walk away if the surgical team cannot quote an annual HPB cancer surgery volume.

Gallbladder cancer staging needs contrast CT of the abdomen, MRI with MRCP (magnetic resonance cholangiopancreatography) to map the bile duct anatomy, and endoscopic ultrasound (EUS) for fine needle aspiration biopsy when needed for tissue diagnosis. PET-CT helps in advanced staging to rule out distant spread. The CA 19-9 tumour marker tracks disease and treatment response. Crucially, molecular testing for HER2, FGFR2 fusions, IDH1 mutations, BRAF, and mismatch repair status is increasingly important for advanced gallbladder cancer because each of these markers opens specific targeted-therapy options.

Walk away if the hospital does not perform molecular biomarker testing on advanced gallbladder cancer cases.

Gallbladder cancer chemotherapy uses gemcitabine + cisplatin as the established standard combination — given as adjuvant chemotherapy after curative surgery and as primary treatment for advanced disease. Capecitabine is the standard adjuvant option after curative-intent surgery. Durvalumab combined with gemcitabine + cisplatin is the newer immunotherapy standard for advanced biliary tract cancers. For advanced disease with specific molecular features, targeted therapies are available: pemigatinib or infigratinib for FGFR2 fusions, ivosidenib for IDH1 mutations, trastuzumab-based combinations for HER2-positive tumours, and pembrolizumab for mismatch repair-deficient tumours. Ask: 'Where can I get my chemotherapy cycles near home?'

Walk away if all chemotherapy is administered at one campus only.

Gallbladder cancer care routinely calls on procedures that need specialised infrastructure — extended radical cholecystectomy, completion radical cholecystectomy after incidental findings, extended hepatectomy when liver involvement is more extensive, Whipple-style resection when the cancer extends into the pancreas or duodenum, common bile duct resection with biliary reconstruction (hepaticojejunostomy), ERCP for biliary stenting when jaundice is present, and percutaneous transhepatic biliary drainage when ERCP is not feasible. NABH-accredited partners signal audited surgical and procedural safety.

Walk away if the hospital cannot name the partner facility for major HPB surgery or for ERCP-based biliary drainage.

Gallbladder cancer treatment can be a substantial financial commitment — major HPB surgery is expensive, chemotherapy continues for many months, and durvalumab immunotherapy or targeted therapies add significantly to the bill. A hospital that isn't empanelled for your insurance or ArogyaSri at the specific centre where your procedure happens can derail planning at the worst moment.

Walk away if cost estimates change after admission — a serious hospital writes them down beforehand.

Gallbladder cancer survivors need close ongoing surveillance — periodic CT scans, CA 19-9 monitoring, and clinical review at defined intervals because recurrence risk is significant, particularly in the first two to three years after surgery. Patients who have had extensive liver resection need monitoring for liver function recovery. Patients with biliary stents need ongoing management with periodic stent changes. Patients on long-course chemotherapy or immunotherapy need management of treatment side effects. Nutritional support is important for many patients given the metabolic demands of treatment. You will see your team frequently. A hospital an hour away makes every visit a half-day; a network of centres close to home — same panel, same protocols, shared records — makes continuity sustainable.

Walk away if you're told you must travel to one campus for every surveillance scan and CA 19-9 check for the next five years.

Hospital infrastructure for gallbladder cancer is tiered at CION. Surveillance imaging, CA 19-9 monitoring, day-care chemotherapy and immunotherapy, biliary stent monitoring, and clinical follow-up happen at the centre nearest your home. Simple cholecystectomy for T1a cancer, extended radical cholecystectomy with liver and lymph node dissection, completion radical cholecystectomy after incidental cancer findings, extended hepatectomy for advanced disease, Whipple-style resection when pancreatic extension is present, and complex biliary reconstruction all run through NABH-accredited partner hospitals with verified hepatobiliary surgical expertise. The same oncology team that consults at one centre stays with you across the network.

About 10–15% of gallbladder cancers are discovered incidentally — found by the pathologist examining a gallbladder specimen removed for routine gallstone surgery. CION operates an urgent pathway for these cases: rapid pathology review, tumour-board discussion of completion surgery candidacy, scheduling of completion radical cholecystectomy through NABH-accredited HPB partners where indicated, and a clear written plan including adjuvant chemotherapy decisions. If your final pathology after gallstone surgery has shown cancer, request an urgent consultation — timing matters.

Contrast CT, MRI, MRCP (magnetic resonance cholangiopancreatography) for biliary tree mapping, and PET-CT for advanced staging are available across six CION centres in Hyderabad. Endoscopic ultrasound with fine needle aspiration biopsy is coordinated through partner gastroenterology services. CA 19-9 testing runs through integrated lab pathways. Every advanced gallbladder cancer case at CION is routed through full biomarker testing — HER2 status, FGFR2 fusion testing, IDH1 mutation, BRAF mutation, and mismatch repair status — to identify patients who may benefit from targeted therapy.

All 11 CION centres in Hyderabad have day-care infusion bays. Gemcitabine + cisplatin as the standard combination for biliary tract cancers, capecitabine as the adjuvant option after curative surgery, durvalumab combined with gemcitabine + cisplatin as the modern immunotherapy standard for advanced disease, and targeted therapies for biomarker-positive cases — pemigatinib or infigratinib for FGFR2 fusions, ivosidenib for IDH1 mutations, trastuzumab combinations for HER2-positive tumours, and pembrolizumab for mismatch repair-deficient tumours are all administered close to home. Oncology-trained nursing, infusion-reaction protocols, and on-site oncologist supervision are standard at every centre.

Where a gallbladder cancer case requires extended radical cholecystectomy with liver and lymph node resection, completion radical cholecystectomy after an incidental cancer finding, extended hepatectomy for locally advanced disease, Whipple-style resection when the cancer extends to the pancreas or duodenum, common bile duct resection with hepaticojejunostomy (creating a new connection between the liver and small intestine), ERCP for biliary stenting when jaundice is present, or percutaneous transhepatic biliary drainage when ERCP is not feasible, CION coordinates the procedure through NABH-accredited partner hospitals with established hepatobiliary surgical programs and intensive-care capacity. NABH accreditation ensures audited compliance with patient-safety, infection-control, and clinical-governance protocols.

Gallbladder cancer surveillance after curative-intent surgery is intensive — periodic CT scans typically every three to six months for the first two years, then less frequently, along with CA 19-9 blood marker tracking and clinical examination. Liver function monitoring is important after extensive hepatic resection. Biliary stent surveillance and stent change schedules are managed when stents are in place. Management of chemotherapy and immunotherapy side effects, nutritional support for the metabolic demands of treatment, pain management for advanced disease, palliative care integration when appropriate, and psychological support are all coordinated within the CION network.

Every gallbladder cancer case at CION is reviewed by the multidisciplinary tumour board before the treatment plan is finalised. The board debates the TNM stage, the surgical approach (simple vs extended radical vs completion radical vs extended hepatectomy), neoadjuvant chemotherapy decisions for borderline-resectable cases, adjuvant chemotherapy planning after curative surgery, biomarker-driven therapy decisions for advanced cases, and surveillance planning. The board produces a written summary that becomes part of your records — and yours to keep. You can take it to any second opinion, anywhere.